3 citations
,
December 2024 in “Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)” This study reported that meloxicam-loaded spanlastics, created using the ethanol injection method, demonstrated potential as a drug delivery system with sustained release and effective entrapment efficiency.
7 citations
,
April 2006 in “Experimental Neurology” Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.
5 citations
,
April 2016 in “PubMed” This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.
2 citations
,
July 1982 in “British Journal of Dermatology” This study reports that retinol acetate inhibited the pro-oxidant effects of benoxaprofen on polymorphonuclear leucocytes in vitro.
June 2019 in “Reactions Weekly” This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.
81 citations
,
February 2000 in “Anti-cancer drugs” In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.
1 citations
,
April 1987 in “American Journal of Nursing” Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.
January 1988 in “Inpharma (Balgowlah)” New retinoids are effective for various skin conditions and are being developed to have fewer side effects.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
January 2026 in “Nutrición Hospitalaria” In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.
July 2025 in “The Journal of Dermatology” This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.
34 citations
,
July 2011 in “International journal of pharmaceutics” This study found that ion-paired solutions significantly improved the skin penetration of risedronate in hairless mice compared to risedronate alone.
September 2024 in “Journal of Cosmetic Dermatology” In this study, researchers found that Ectoin, derived from halophilic bacteria, can mitigate stress-related skin damage by reducing cortisone's inhibitory effects on essential skin proteins and decreasing UVB-induced glucocorticoid activity, highlighting its potential as a preventative agent for stress-induced skin issues.
73 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
February 2026 in “Indian Journal of Skin Allergy” This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.
86 citations
,
July 1990 in “British Journal of Pharmacology” Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.
53 citations
,
August 2014 in “Cochrane library” This review found no evidence supporting the efficacy of methotrexate for inducing remission in active ulcerative colitis compared to placebo or active comparators.
This article reviews numerous drug reactions and interactions for various medications and does not present new research findings.
This article discusses variations in retinoid pharmacokinetics affecting their toxicity and clinical efficacy, but reports no new results; the authors emphasize considering toxicity in selecting suitable compounds.
1 citations
,
January 2023 in “Cutis” This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.
5 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” This case report describes a 40-year-old woman who developed erythema annulare centrifugum, a type of skin rash, likely triggered by taking the drug aceclofenac.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
May 2025 in “Süleyman Demirel Üniversitesi Fen Edebiyat Fakültesi Fen Dergisi” In this study, researchers found that minoxidil is compatible with excipients such as Beta-cyclodextrin and cellulose, while it is incompatible with Eudragit S 100 and mannitol, indicating potential formulation challenges in pharmaceutical applications.
8 citations
,
January 2013 in “European Journal of Dermatology” This article reviews the use of alitretinoin for corticosteroid-refractory chronic hand eczema and explores its potential therapeutic benefits in other skin conditions, but reports no clinical results.
143 citations
,
May 2002 in “PubMed” This study found that the retinoid LGD1069 suppressed mammary tumorigenesis in a mouse model without observable toxicity, while TTNPB showed modest effects but was associated with significant toxicity.
July 2026 in “Dermatology and Therapy” In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.
1 citations
,
June 2013 in “Annals of the Rheumatic Diseases” This study observed that while all DMARD regimens had similar safety profiles, the leflunomide group experienced the most serious side effects leading to therapy discontinuation.
November 2001 in “Oncology Times” The committee unanimously voted against recommending approval of the injectable cisplatin/epinephrine gel IntraDose for certain head and neck cancer patients, citing insufficient clinical benefit and concerns about toxicity in this study.